Pacira BioSciences Files Definitive Proxy Statement

Ticker: PCRX · Form: DEF 14A · Filed: Apr 22, 2024 · CIK: 1396814

Pacira Biosciences, Inc. DEF 14A Filing Summary
FieldDetail
CompanyPacira Biosciences, Inc. (PCRX)
Form TypeDEF 14A
Filed DateApr 22, 2024
Risk Levellow
Pages14
Reading Time17 min
Key Dollar Amounts$100 million
Sentimentneutral

Sentiment: neutral

Topics: Pacira BioSciences, PCRX, DEF 14A, Proxy Statement, Non-opioid pain management

TL;DR

<b>Pacira BioSciences filed its Definitive Proxy Statement for the period ending June 11, 2024, outlining its commitment to non-opioid pain management solutions.</b>

AI Summary

Pacira BioSciences, Inc. (PCRX) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. Pacira BioSciences, Inc. (PCRX) filed a Definitive Proxy Statement (DEF 14A) on April 22, 2024. The filing pertains to the company's proxy statement for the period ending June 11, 2024. Pacira BioSciences is the industry leader in non-opioid pain management and regenerative health solutions. Key products include EXPAREL (launched 2012) and ZILRETTA (acquired 2021). The company's mission is to provide opioid alternatives using enhanced recovery after surgery protocols.

Why It Matters

For investors and stakeholders tracking Pacira BioSciences, Inc., this filing contains several important signals. This filing is a standard procedural document for publicly traded companies, providing shareholders with information regarding upcoming meetings and voting matters. It details Pacira's strategic focus on non-opioid pain management, highlighting key products like EXPAREL and ZILRETTA, which are central to their business model and future growth.

Risk Assessment

Risk Level: low — Pacira BioSciences, Inc. shows low risk based on this filing. The filing is a routine proxy statement with no new material financial or operational information, thus posing a low risk.

Analyst Insight

Shareholders should review the proxy statement for details on upcoming voting matters and executive compensation.

Key Numbers

  • 2024-04-22 — Filing Date (DEF 14A filing date)
  • 2024-06-11 — Period of Report (Conformed period of report)
  • 2012 — EXPAREL Launch Year (Commercial launch of EXPAREL in the United States)
  • 2019 — iovera Acquisition Year (Acquisition of the iovera system)
  • 2021 — ZILRETTA Acquisition Year (Acquisition of ZILRETTA)

Key Players & Entities

  • Pacira BioSciences, Inc. (company) — Filer name
  • PCRX (company) — Nasdaq ticker symbol
  • DEF 14A (filing) — Form type
  • 2024-04-22 (date) — Filing date
  • 2024-06-11 (date) — Period of report
  • EXPAREL (product) — Long-acting local analgesic
  • ZILRETTA (product) — Product acquired in 2021
  • 2012 (date) — Commercial launch year for EXPAREL

FAQ

When did Pacira BioSciences, Inc. file this DEF 14A?

Pacira BioSciences, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 22, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Pacira BioSciences, Inc. (PCRX).

Where can I read the original DEF 14A filing from Pacira BioSciences, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Pacira BioSciences, Inc..

What are the key takeaways from Pacira BioSciences, Inc.'s DEF 14A?

Pacira BioSciences, Inc. filed this DEF 14A on April 22, 2024. Key takeaways: Pacira BioSciences, Inc. (PCRX) filed a Definitive Proxy Statement (DEF 14A) on April 22, 2024.. The filing pertains to the company's proxy statement for the period ending June 11, 2024.. Pacira BioSciences is the industry leader in non-opioid pain management and regenerative health solutions..

Is Pacira BioSciences, Inc. a risky investment based on this filing?

Based on this DEF 14A, Pacira BioSciences, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement with no new material financial or operational information, thus posing a low risk.

What should investors do after reading Pacira BioSciences, Inc.'s DEF 14A?

Shareholders should review the proxy statement for details on upcoming voting matters and executive compensation. The overall sentiment from this filing is neutral.

Glossary

DEF 14A
Definitive Proxy Statement filed with the SEC. (This filing provides shareholders with information for voting at the annual meeting.)
EXPAREL
A long-acting local analgesic (bupivacaine liposome injectable suspension). (It is a key product for Pacira BioSciences in non-opioid pain management.)
pMVL
Proprietary multivesicular liposome drug delivery technology. (This technology encapsulates drugs for sustained release, underpinning products like EXPAREL.)
iovera system
A handheld cryoanalgesia device for targeted nerve treatment. (Acquired by Pacira in 2019, it expands their non-opioid pain management portfolio.)
ZILRETTA
A product for osteoarthritis knee pain (triamcinolone acetonide extended-release injectable suspension). (Acquired by Pacira in 2021, it further diversifies their pain management offerings.)

Filing Stats: 4,304 words · 17 min read · ~14 pages · Grade level 16.3 · Accepted 2024-04-22 16:16:02

Key Financial Figures

  • $100 million — hich we believe is going to grow into a $100 million annual opportunity over time. We have a

Filing Documents

Executive Compensation Highlights

Executive Compensation Highlights 17 CORPORATE GOVERNANCE AND BOARD MATTERS 17 Proposal 1 —Election of Class I Directors 17 Board Composition 18 Nominees for Election 21 Directors Continuing in Office 27 Director Nomination Process 28 Board Elects Independent Board Chair NEW 28 Majority Vote Director Resignation Policy 28 Board Meeting Annual Schedule 28 Director Independence 29 Board Committees 32 Board and Committee Meetings Attendance 32 Director Attendance at Annual Meeting of Stockholders 32 Code of Business Conduct and Ethics 33 Corporate Governance Documents 33 Board Leadership Structure and Board's Role in Risk Oversight 36 Anti-Hedging and Anti-Pledging Policy 36 Communication with the Board 36 Related Person Transactions 38 Shareholder Rights NEW 39 Director Compensation 41 Director Stock Ownership Guidelines 43 AUDIT MATTERS 43 Proposal 2 —Ratification of the Appointment of Independent Auditors 43 Annual Evaluation and Selection of KPMG LLP 44 Auditor Fees 44 Audit Committee Pre-Approval Policy and Procedures 45 Report of the Audit Committee 47 EXECUTIVE OFFICERS 51

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 51 Proposal 3 —Advisory Vote to Approve Executive Compensation 52 Compensation Discussion and Analysis 69 Compensation Committee Report 70 Compensation Tables 80 Pay Versus Performance 85 CEO Pay Ratio 87 STOCK OWNERSHIP INFORMATION 87 Principal Stockholders 91 INFORMATION ABOUT THE ANNUAL MEETING AND VOTING 96 ADDITIONAL INFORMATION 96 Householding 96 Stockholder Proposals 97 Other Matters A-1 APPENDIX A—RECONCILIATION OF U.S. GAAP NET INCOME TO ADJUSTED EBITDA TABLE OF CONTENTS

Forward-Looking Statements

Forward-Looking Statements

Forward-Looking Statements

Forward-Looking Statements This Proxy Statement includes estimates, projections, statements relating to our business plans, objectives and expected operating results that are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may appear throughout this proxy statement. These forward-looking statements generally are identified by the words "anticipate," "believe," "can," "could," "estimate," "expect," "future," "intend," "may," "opportunity," "plan," "project," "should," "strategy," "will," "will be," "will continue," "will likely result," "would," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties that may cause actual results to differ materially. We describe risks and uncertainties that could cause actual results and events to differ materially in "Risk Factors," "Quantitative and Qualitative Disclosures about Market Risk," and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. We undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. TABLE OF CONTENTS Pacira BioSciences, Inc. 2024 Proxy Statement | 1 TABLE OF CONTENTS 2024 Proxy Statement Summary This proxy statement is furnished to stockholders of Pacira BioSciences, Inc. in connection with the solicitation of proxies by our board of directors (the "board"). In this proxy statement, unless expressly stated otherwise or the context other

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.